June 25, 2026—Merck (Darmstadt, Germany) has entered into a definitive agreement to acquire Minneapolis-based Bio-Techne Corp. for approximately $11.3 billion.
The transaction brings together two complementary life sciences organizations to support customers across the spectrum of life science workflows, from discovery and translational research through development, testing, and commercial manufacturing. It would also deliver on Merck’s mid- to long-term strategic agenda, which focuses on high-growth value drivers, integrated workflows, platformed capabilities, and scaling and sourcing innovation through M&A.
Bio-Techne brings to Merck a portfolio of cytokines, growth factors, antibodies, and immunoassay kits and includes ProteinSimple, a manufacturer of automated protein detection and analysis instruments, strengthening Merck’s analytical and bioprocess solutions. In addition, Bio-Techne’s RNAscope and related in situ hybridization technologies would expand Merck’s capabilities in spatial biology and diagnostics.
The transaction is expected to close by late 2026 or early 2027, subject to customary closing conditions.